Immunome (IMNM) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

IMNM Stock Forecast

Immunome stock forecast is as follows: an average price target of $30.33 (represents a 225.08% upside from IMNM’s last price of $9.33) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

IMNM Price Target

The average price target for Immunome (IMNM) is $30.33 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $35.00 to $23.00. This represents a potential 225.08% upside from IMNM's last price of $9.33.

IMNM Analyst Ratings

Buy

According to 4 Wall Street analysts, Immunome's rating consensus is 'Buy'. The analyst rating breakdown for IMNM stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Immunome Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Aug 13, 2024	Biren Amin	Piper Sandler	$23.00	$12.64	81.96%	146.52%
Apr 15, 2024	Michael Schmidt	Guggenheim	$35.00	$20.58	70.07%	275.13%
Apr 01, 2024	David Nierengarten	Wedbush	$33.00	$24.68	33.71%	253.70%

Row per page

Go to

The latest Immunome stock forecast, released on Aug 13, 2024 by Biren Amin from Piper Sandler, set a price target of $23.00, which represents a 81.96% increase from the stock price at the time of the forecast ($12.64), and a 146.52% increase from IMNM last price ($9.33).

Immunome Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	3
Avg Price Target	-	-	$30.33
Last Closing Price	$9.33	$9.33	$9.33
Upside/Downside	-100.00%	-100.00%	225.08%

In the current month, the average price target of Immunome stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Immunome's last price of $9.33. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 16, 2024	Cowen & Co.	Buy	Buy	Hold
Aug 13, 2024	Piper Sandler	Overweight	Overweight	Hold
May 31, 2024	Piper Sandler	-	Overweight	Initialise
Apr 15, 2024	Guggenheim	-	Buy	Initialise
Apr 01, 2024	Wedbush	Outperform	Outperform	Hold

Row per page

Go to

Immunome's last stock rating was published by Cowen & Co. on Sep 16, 2024. The company gave IMNM a "Buy" rating, the same as its previous rate.

Immunome Financial Forecast

Immunome Revenue Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Dec 20	Sep 20
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$19.79M	$15.65M	$10.86M	$6.81M	$1.65M	$294.55K	$2.91M	$2.91M	$2.91M	$2.91M	$2.91M	$2.91M	$3.16M	$2.29M	$1.87M	$2.80M	$2.07M	$2.10M	$390.50K
High Forecast	$22.54M	$17.82M	$12.37M	$7.75M	$1.88M	$335.43K	$3.31M	$3.31M	$3.31M	$3.31M	$3.31M	$3.31M	$3.59M	$2.61M	$1.87M	$3.19M	$2.35M	$2.10M	$390.50K
Low Forecast	$16.98M	$13.42M	$9.31M	$5.84M	$1.41M	$252.62K	$2.50M	$2.50M	$2.50M	$2.50M	$2.50M	$2.50M	$2.71M	$1.96M	$1.87M	$2.40M	$1.77M	$2.10M	$390.50K
# Analysts	2	2	2	2	2	2	2	2	1	1	1	1	4	2	1	1	1	1	1
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Immunome's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. IMNM's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Immunome EBITDA Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Dec 20	Sep 20
# Analysts	2	2	2	2	2	2	2	2	1	1	1	1	4	2	1	1	1	1	1
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-3.81M	$-8.19M
Avg Forecast	$11.88M	$9.39M	$6.52M	$4.08M	$988.80K	$176.73K	$1.75M	$1.75M	$1.75M	$1.75M	$1.75M	$1.75M	$1.89M	$1.37M	$1.12M	$1.68M	$1.24M	$1.26M	$234.30K
High Forecast	$13.52M	$10.69M	$7.42M	$4.65M	$1.13M	$201.26K	$1.99M	$1.99M	$1.99M	$1.99M	$1.99M	$1.99M	$2.16M	$1.56M	$1.12M	$1.91M	$1.41M	$1.26M	$234.30K
Low Forecast	$10.19M	$8.05M	$5.59M	$3.50M	$848.04K	$151.57K	$1.50M	$1.50M	$1.50M	$1.50M	$1.50M	$1.50M	$1.62M	$1.18M	$1.12M	$1.44M	$1.06M	$1.26M	$234.30K
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3.02%	-34.96%

undefined analysts predict IMNM's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Immunome's previous annual EBITDA (undefined) of $NaN.

Immunome Net Income Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Dec 20	Sep 20
# Analysts	2	2	2	2	2	2	2	2	1	1	1	1	4	2	1	1	1	1	1
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-4.07M	$-8.38M
Avg Forecast	$-25.47M	$-30.13M	$-34.82M	$-37.09M	$-39.31M	$-43.01M	$-42.23M	$-41.93M	$-46.24M	$-43.83M	$-42.99M	$-42.02M	$-39.74M	$-33.20M	$-22.84M	$-40.94M	$-16.46M	$-17.38M	$-22.78M
High Forecast	$-20.75M	$-24.55M	$-28.37M	$-30.23M	$-32.03M	$-35.05M	$-34.41M	$-34.17M	$-37.68M	$-35.72M	$-35.03M	$-34.25M	$-35.32M	$-27.05M	$-18.61M	$-33.36M	$-13.52M	$-17.38M	$-22.78M
Low Forecast	$-30.06M	$-35.56M	$-41.10M	$-43.78M	$-46.40M	$-50.77M	$-49.85M	$-49.50M	$-54.58M	$-51.74M	$-50.74M	$-49.61M	$-44.70M	$-39.19M	$-26.96M	$-48.33M	$-21.75M	$-17.38M	$-22.78M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.23%	0.37%

Immunome's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. IMNM's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Immunome SG&A Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Dec 20	Sep 20
# Analysts	2	2	2	2	2	2	2	2	1	1	1	1	4	2	1	1	1	1	1
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$2.24M	$1.17M
Avg Forecast	$21.39M	$16.91M	$11.73M	$7.35M	$1.78M	$318.25K	$3.14M	$3.14M	$3.14M	$3.14M	$3.14M	$3.14M	$3.41M	$2.47M	$2.02M	$3.03M	$2.23M	$2.27M	$421.92K
High Forecast	$24.35M	$19.25M	$13.36M	$8.37M	$2.03M	$362.42K	$3.58M	$3.58M	$3.58M	$3.58M	$3.58M	$3.58M	$3.88M	$2.82M	$2.02M	$3.45M	$2.54M	$2.27M	$421.92K
Low Forecast	$18.34M	$14.50M	$10.06M	$6.31M	$1.53M	$272.94K	$2.70M	$2.70M	$2.70M	$2.70M	$2.70M	$2.70M	$2.92M	$2.12M	$2.02M	$2.59M	$1.92M	$2.27M	$421.92K
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.99%	2.78%

Immunome's average Quarter SG&A projection for Dec 23 is $2.23M, based on 1 Wall Street analysts, with a range of $1.92M to $2.54M. The forecast indicates a -0.23% fall compared to IMNM last annual SG&A of $2.24M (Dec 20).

Immunome EPS Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Dec 20	Sep 20
# Analysts	2	2	2	2	2	2	2	2	1	1	1	1	4	2	1	1	1	1	1
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.40	$-0.90
Avg Forecast	$-0.42	$-0.50	$-0.58	$-0.62	$-0.65	$-0.71	$-0.70	$-0.70	$-0.77	$-0.73	$-0.71	$-0.70	$-0.66	$-0.55	$-0.38	$-0.68	$-0.27	$-0.29	$-0.38
High Forecast	$-0.34	$-0.41	$-0.47	$-0.50	$-0.53	$-0.58	$-0.57	$-0.57	$-0.63	$-0.59	$-0.58	$-0.57	$-0.59	$-0.45	$-0.31	$-0.55	$-0.22	$-0.29	$-0.38
Low Forecast	$-0.50	$-0.59	$-0.68	$-0.73	$-0.77	$-0.84	$-0.83	$-0.82	$-0.91	$-0.86	$-0.84	$-0.82	$-0.74	$-0.65	$-0.45	$-0.80	$-0.36	$-0.29	$-0.38
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.38%	2.37%

According to undefined Wall Street analysts, Immunome's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to IMNM previous annual EPS of $NaN (undefined).

Immunome Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
INAB	IN8bio	$0.32	$14.00	4275.00%	Buy
ANTX	AN2 Therapeutics	$1.30	$8.75	573.08%	Buy
LIFE	aTyr Pharma	$1.90	$11.00	478.95%	Buy
MOLN	Molecular Partners	$5.20	$29.00	457.69%	Buy
AVTE	Aerovate Therapeutics	$2.66	$13.00	388.72%	Hold
GANX	Gain Therapeutics	$1.66	$7.00	321.69%	Buy
ANEB	Anebulo Pharmaceuticals	$1.52	$6.00	294.74%	Buy
ACRV	Acrivon Therapeutics	$6.50	$21.83	235.85%	Buy
IMNM	Immunome	$9.33	$30.33	225.08%	Buy
RZLT	Rezolute	$5.01	$13.50	169.46%	Buy
ANAB	AnaptysBio	$20.31	$52.00	156.03%	Buy
CELC	Celcuity	$12.78	$31.50	146.48%	Buy
ADAG	Adagene	$2.09	$5.00	139.23%	Buy
MLYS	Mineralys Therapeutics	$12.60	$30.00	138.10%	Buy
IKNA	Ikena Oncology	$1.70	$1.33	-21.76%	Buy
CYT	Cyteir Therapeutics	$3.02	$2.00	-33.77%	Sell

IMNM Forecast FAQ

Is Immunome a good buy?

Yes, according to 4 Wall Street analysts, Immunome (IMNM) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of IMNM's total ratings.

What is IMNM's price target?

Immunome (IMNM) average price target is $30.33 with a range of $23 to $35, implying a 225.08% from its last price of $9.33. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Immunome stock go up soon?

According to Wall Street analysts' prediction for IMNM stock, the company can go up by 225.08% (from the last price of $9.33 to the average price target of $30.33), up by 275.13% based on the highest stock price target, and up by 146.52% based on the lowest stock price target.

Can Immunome stock reach $14?

IMNM's average twelve months analyst stock price target of $30.33 supports the claim that Immunome can reach $14 in the near future.

What are Immunome's analysts' financial forecasts?

Immunome's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $7.76M (high $8.84M, low $6.66M), average EBITDA is $4.66M (high $5.3M, low $3.99M), average net income is $-166M (high $-136M, low $-197M), average SG&A $8.39M (high $9.55M, low $7.19M), and average EPS is $-2.765 (high $-2.253, low $-3.264). IMNM's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $53.11M (high $60.48M, low $45.55M), average EBITDA is $31.86M (high $36.29M, low $27.33M), average net income is $-128M (high $-104M, low $-151M), average SG&A $57.38M (high $65.34M, low $49.21M), and average EPS is $-2.118 (high $-1.726, low $-2.5).